Evaluation of insulin resistance in acromegalic patients before and after treatment with somatostatin analogues

Cristina L. Ronchi, E. Orsi, C. Giavoli, V. Cappiello, P. Epaminonda, P. Beck-Peccoz, M. Arosio

Research output: Contribution to journalArticlepeer-review


Many studies have recently shown that simple computer-solved indices, based on fasting glucose and insulin levels, closely mirror the euglycemic clamp technique in studying insulin resistance or pancreatic insulin secretion. Few data are at present available on the evaluation of these novel indices in acromegalic patients, known to be GH-dependent insulin-resistant subjects, in particular during medical treatment with somatostatin analogues. Indeed, these drugs are able to inhibit not only GH and IGF-I levels, but also insulin and glucagon pancreatic secretion, with contrasting effects on glucose metabolism. In this study, insulin resistance was evaluated by the homeostasis model assessment (HOMA-IR) and insulin sensitivity by quantitative insulin check index (QUICKI) in 27 normoglycemic acromegalic patients, before and after 6-month therapy with somatostatin analogues (lanreotide-SR 30-60 mg every 7-28 days in 15 and octreotide-LAR 20-30 mg every 28 days in 12). Thirty-five age- and sex-matched healthy subjects and 17 surgically treated acromegalic patients (5 cured and 12 not cured) were studied as control groups. Before medical treatment, HOMA-IR was higher in acromegalic patients than in healthy controls (4±3 vs 1.7±0.7, p

Original languageEnglish
Pages (from-to)533-538
Number of pages6
JournalJournal of Endocrinological Investigation
Issue number6
Publication statusPublished - Jun 2003


  • Acromegaly
  • Glucose metabolism
  • Insulin resistance
  • Somatostatin analogues

ASJC Scopus subject areas

  • Endocrinology


Dive into the research topics of 'Evaluation of insulin resistance in acromegalic patients before and after treatment with somatostatin analogues'. Together they form a unique fingerprint.

Cite this